In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program. 

Related News Articles

Headline
A new memorandum from the Centers for Medicare & Medicaid Services is reinforcing the agency’s role in enforcing regulatory expectations that patients and…
Headline
The Workgroup for Electronic Data Interchange advisory group yesterday urged Health and Human Services Secretary Xavier Becerra to work closely with standards…
Perspective
After Election Day, lawmakers will return to Washington to consider many important issues, including funding the government, the annual must-pass defense bill…
Headline
At an AHA virtual policy briefing today for congressional staff, hospital and health system leaders urged Congress to prioritize actions to address the…
Headline
As Congress begins to focus on its year-end agenda, AHA today urged lawmakers to prioritize certain actions to help hospitals and health systems address rising…
Headline
Hospitals serving marginalized urban communities need additional federal support so they can meet their mission of advancing health for the patients and…